Dynavax Technologies Corp (DVAX) concluded trading on Wednesday at a closing price of $9.72, with 6.23 million shares of worth about $60.57 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -17.49% during that period and on May 07, 2025 the price saw a loss of about -10.99%. Currently the company’s common shares owned by public are about 123.70M shares, out of which, 116.71M shares are available for trading.
Stock saw a price change of -17.28% in past 5 days and over the past one month there was a price change of -22.18%. Year-to-date (YTD), DVAX shares are showing a performance of -23.88% which decreased to -17.21% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $9.74 but also hit the highest price of $14.63 during that period. The average intraday trading volume for Dynavax Technologies Corp shares is 2.56 million. The stock is currently trading -12.03% below its 20-day simple moving average (SMA20), while that difference is down -22.54% for SMA50 and it goes to -19.62% lower than SMA200.
Dynavax Technologies Corp (NASDAQ: DVAX) currently have 123.70M outstanding shares and institutions hold larger chunk of about 102.47% of that.
The stock has a current market capitalization of $1.19B and its 3Y-monthly beta is at 1.17. It has posted earnings per share of -$0.53 in the same period. It has Quick Ratio of 10.84 while making debt-to-equity ratio of 0.55. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for DVAX, volatility over the week remained 4.70% while standing at 4.96% over the month.
Stock’s fiscal year EPS is expected to drop by -229.00% while it is estimated to increase by 306.98% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Goldman on February 11, 2025 offering a Sell rating for the stock and assigned a target price range of between $15 and $12 to it. Coverage by Goldman stated Dynavax Technologies Corp (DVAX) stock as a Neutral in their note to investors on February 01, 2024, suggesting a price target of $20 for the stock. On September 27, 2022, JMP Securities Initiated their recommendations, while on January 06, 2022, Goldman Resumed their ratings for the stock with a price target of $38. Stock get a Buy rating from Goldman on August 06, 2021.
